Tentative Approval for Generic Zofran Injection
American Pharmaceutical Partners has received two tentative approvals from the FDA for its Abbreviated New Drug Applications (ANDAs) for Generic Ondansetron Injection, USP, in single-dose and multiple-dose vials. As the generic equivalent of GlaxoSmithKline’s Zofran drug Injection, it is indicated for the prevention of postoperative and chemotherapy-related nausea and vomiting.
